Jim Cramer on Agilent Technologies: "I Don't Think You Need It"

Agilent Technologies, Inc. (NYSE:

) is one of the . A caller asked if the stock will ever come back, and here’s what Cramer had to say in response:

You know, they do so much test and measurement that is biotech. It’s almost like a Danaher, which stopped working. Danaher, Agilent, I don’t think you need it.

A stock market chart. Photo by Arturo A on Pexels

Agilent Technologies, Inc. (NYSE:A) provides instruments, software, and services for life sciences, diagnostics, and chemical analysis, including chromatography, spectroscopy, genomics, and laboratory automation solutions. Cramer discussed the pre- and post-COVID performance of the stock during the December 1, 2025, as he said:

Last week, just before Thanksgiving, I got the chance to speak with Agilent Technologies. That’s an arms dealer to the life sciences industry. A long time ago, this stock, known as letter A for its stock symbol, was a great growth vehicle. In the decade before COVID, Agilent’s chart was just a thing of beauty. Then, when the pandemic got rolling, the stock roared even higher, and ever since the pandemic receded, things got choppy for this one but also for the entire industry. The life sciences companies had all the equipment they needed, so the whole group spent years in the dog house.

While we acknowledge the potential of A as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the